New sepsis treatment draws skepticism

One doctor’s claims of having a new and effective treatment for sepsis may be true, NPR reports, but he needs better clinical evidence to prove it.

Sepsis kills about 300,000 people a year, making it the leading cause of death in hospitals. So it would make a big difference if others can replicate the results of Paul Marik, MD, an intensive care physician at the Eastern Virginia Medical Center in Norfolk. He said using a mix of intravenous corticosteroids, vitamin C and vitamin B, along with careful management of fluids, he treated 150 sepsis patients and had only one die of the condition.

But his results don’t come from a randomized trial run at multiple hospitals, and doing such an experiment may take up to two years, leaving the medical world skeptical of Marik’s promises in the meantime.

“Nothing has worked despite all the great ideas people have had, often ballyhooed with observational data like this, claiming that it's a big effect,” said former Food and Drug Administration Commissioner Robert Califf, MD.

Other doctors, however, are already planning on using Marik’s techniques, even without more robust clinical evidence.

Read the full article below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.